PURPOSE: 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a well-established method in the follow-up of patients with differentiated thyroid carcinoma (DTC), elevated thyroglobulin (Tg) and negative 131I scans. This retrospective clinical study was designed to evaluate the impact of computed tomography (CT) and that of FDG-PET in combined FDG-PET/CT examinations on the restaging of DTC patients. METHODS: Forty-seven FDG-PET/CT scans of 33 patients with a history of DTC, elevated Tg levels and negative 131I uptake or additionally suspected 131I-negative lesions were studied. PET and CT images were analysed independently by an experienced nuclear medicine specialist and a radiologist. Afterwards a final consensus interpretation, the gold standard in our department, was provided for the fused PET/CT images and, if available, for supplementary investigations. RESULTS: Thirty-five investigations (74%) revealed pathological FDG-PET/CT findings. In summary, 25 local recurrences, 62 lymph node metastases and 122 organ metastases (41 lung, 60 bone, 21 other organs) were diagnosed. In 36 out of 47 examinations (77%), the original PET diagnoses were modified in the final consensus interpretation owing to the CT assessments. In 8 of the 35 pathological FDG-PET/CT examinations (23%), the final consensus interpretation of the PET/CT images led to an alteration in the treatment plan. CONCLUSION: PET/CT is a powerful fusion of two pre-existing imaging modalities, which not only improves the diagnostic value in restaging DTC patients with elevated Tg and negative 131I scan, but also provides accurate information regarding subsequent treatment options and may lead to a change in treatment management.
PURPOSE:18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a well-established method in the follow-up of patients with differentiated thyroid carcinoma (DTC), elevated thyroglobulin (Tg) and negative 131I scans. This retrospective clinical study was designed to evaluate the impact of computed tomography (CT) and that of FDG-PET in combined FDG-PET/CT examinations on the restaging of DTCpatients. METHODS: Forty-seven FDG-PET/CT scans of 33 patients with a history of DTC, elevated Tg levels and negative 131I uptake or additionally suspected 131I-negative lesions were studied. PET and CT images were analysed independently by an experienced nuclear medicine specialist and a radiologist. Afterwards a final consensus interpretation, the gold standard in our department, was provided for the fused PET/CT images and, if available, for supplementary investigations. RESULTS: Thirty-five investigations (74%) revealed pathological FDG-PET/CT findings. In summary, 25 local recurrences, 62 lymph node metastases and 122 organ metastases (41 lung, 60 bone, 21 other organs) were diagnosed. In 36 out of 47 examinations (77%), the original PET diagnoses were modified in the final consensus interpretation owing to the CT assessments. In 8 of the 35 pathological FDG-PET/CT examinations (23%), the final consensus interpretation of the PET/CT images led to an alteration in the treatment plan. CONCLUSION: PET/CT is a powerful fusion of two pre-existing imaging modalities, which not only improves the diagnostic value in restaging DTCpatients with elevated Tg and negative 131I scan, but also provides accurate information regarding subsequent treatment options and may lead to a change in treatment management.
Authors: Suzanne L Aquino; Landon B Kuester; Victorine V Muse; Elkan F Halpern; Alan J Fischman Journal: Eur J Nucl Med Mol Imaging Date: 2006-03-03 Impact factor: 9.236
Authors: B O Helal; P Merlet; M E Toubert; B Franc; C Schvartz; H Gauthier-Koelesnikov; A Prigent; A Syrota Journal: J Nucl Med Date: 2001-10 Impact factor: 10.057
Authors: D Simon; C Körber; M Krausch; J Segering; P Groth; R Görges; F Grünwald; H W Müller-Gärtner; C Schmutzler; J Köhrle; H D Röher; C Reiners Journal: Eur J Nucl Med Mol Imaging Date: 2002-03-13 Impact factor: 9.236
Authors: Lee A Zimmer; Barry McCook; Carolyn Meltzer; Melanie Fukui; Daphne Bascom; Carl Snyderman; David W Townsend; Jonas T Johnson Journal: Otolaryngol Head Neck Surg Date: 2003-02 Impact factor: 3.497
Authors: Alessia David; Annabella Blotta; Roberta Rossi; Maria Chiara Zatelli; Marta Bondanelli; Elio Roti; Lewis E Braverman; Luciano Busutti; Ettore C degli Uberti Journal: Thyroid Date: 2005-02 Impact factor: 6.568
Authors: Karin M van Tol; Pieter L Jager; D Albertus Piers; Jan Pruim; Elisabeth G E de Vries; Robin P F Dullaart; Thera P Links Journal: Thyroid Date: 2002-05 Impact factor: 6.568
Authors: Clive S Grant; Geoffrey B Thompson; David R Farley; Melanie L Richards; Brian P Mullan; Ian D Hay Journal: World J Surg Date: 2008-05 Impact factor: 3.352
Authors: Jennifer M J Schreinemakers; Menno R Vriens; Nuria Munoz-Perez; Marlon A Guerrero; Insoo Suh; Inne H M Borel Rinkes; Jessica Gosnell; Wen T Shen; Orlo H Clark; Quan-Yang Duh Journal: World J Surg Oncol Date: 2012-09-17 Impact factor: 2.754